Polycystic Ovarian Syndrome/Disease (PCOS/PCOD) Market
By Diagnosis (Pelvic Examination, Ultrasound, Blood Test),
By Drug Class (Oral Contraceptives, Insulin Sensitizing Agents, Antiandrogens, Ornithine Decarboxylase Inhibitors, Aromatase Inhibitors & SERMs, Others),
By Distribution and Usage (Hospitals, Pharmacies, and Drug Stores, e-commerce, Clinics),
By Surgery (Wedge Resection, Laparoscopic Drilling),
By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa):
Polycystic Ovarian Syndrome/Disease (PCOS/PCOD) Market - Global Analysis and Forecast 2023-2033
The global polycystic ovarian syndrome or disease market to worth more than USD 5,285.9 Million by 2033.
The global polycystic ovarian syndrome market is developing and expanding as the condition's prevalence rises and patient awareness grows. People's improved buying power and understanding of PCOS are expected to drive growth in the global PCOS drugs market. Moreover, Innovations in PCOS screening technologies, an increase in demand for PCOS drugs, and the availability of PCOS therapy all impact the market's growth. PCOS affects around 5-10% of women of reproductive age (12– 45 years old). It is regarded as one of the leading causes of female infertility and the most common endocrine disorder in reproductive-age women. If pregnancy is desired, first-line pharmaceuticals, such as clomiphene or letrozole, or second-line drugs, such as metformin, are suggested by the American Family Physician (AAFP) Guideline 2016 and the Australian Family Physician (AFP) Guidelines 2012. Although PCOS is a major cause of infertility in women and treatment response deteriorates over the period, surgery performed via the abdomen with a thin microscope is commonly preferred worldwide.
Several corporations are focusing on cooperation with other companies with items in advanced stages of innovation to gain faster approval and better distribution channels for their products. Major manufacturing and pharmaceutical companies are developing novel products to strengthen their product pipelines around the world. Similarly, many significant players in the ovarian syndrome therapeutics market have joined consolidation efforts to accelerate R&D. For instance, In October 2021, The FDA approved Eli Lilly and Company's Verzenio for the treatment of adult patients with Hormone Receptor Positive (HR+) Human Epidermal Growth Factor 2 Negative (HER2-), early breast cancer, and gynecological malignancies.
According to the CXOs and primary research conducted, Manufacturers are broadening their offering of medicine formulations and dietary prepared items to boost profits from PCOS treatment drugs while improving quality of life. This is significant since the number of persons diagnosed with PCOS has risen dramatically in recent years. Moreover, the emergence of new and innovative solutions is projected to enhance adoption rates, driving the market in the coming years. Pharma companies may target huge patient populations by focusing on growing markets in Asia Pacific and Africa.
The polycystic ovarian syndrome or disease market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. In line with the studied region, the North American region will witness the highest market share, followed by Europe, Asia-Pacific, Latin America, and Middle East & Africa. The Asia-Pacific polycystic ovarian syndrome treatment market is predicted to increase due to a huge generation with a lot of discretionary income and major manufacturers' increasing focus on expanding their regional footprint in emerging Asia-Pacific countries. The major companies operating within the market are Allergan, Apothecus Pharmaceutical Cor, Amgen, Blairex Laboratories Inc, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc, JSC BIOCAD, Novartis A, Pfizer, Teva Pharmaceutical Industries.
